This is the authors' abstract. We don't add key points for this paper.
The liver is the most common site of metastases for colorectal cancer. Complete resection in some patients with resectable liver metastases (LM) can lead to long-term survival and cure. Adjuvant systemic chemotherapy after complete resection of LM improves recurrence-free survival; however, the overall survival benefit is not clear. In selected patients, preoperative systemic treatment for metastatic colorectal cancer can convert unresectable to resectable cancer. This review will focus on patient selection, and integration of perioperative and postoperative systemic treatment to surgery in resectable and initially unresectable LM. Additionally, new drugs and biomarkers will be discussed.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2021) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: